Login to Your Account

Clinic Roundup

Thursday, March 8, 2012
• Isis Pharmaceuticals Inc., of Carlsbad, Calif., said it started a Phase I trial of ISIS-STAT3Rx, a Generation 2.5 antisense drug designed to treat cancer by specifically reducing the production of signal transducer and activator of transcription 3, or STAT3, which is overexpressed in numerous cancer types.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription